Press Releases Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:55:00 13/01/2026 GMT			After hours 19:53:06
80.50 ^EUR	-2.32%		81.34	+1.05%

06:24pm	Thermo Fisher wins contracts as pharma shifts production to US, CEO says	RE
01:38pm	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Portfolio of Oral Immunology Programs	CI

Press Releases

01-12	Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes	GL
01-09	UPC's Court Of Appeal Overturns First Instance Decision In Amgen V. Sanofi And Regeneron	AQ
01-05	Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes	GL
12-25	Sanofi acquires Dynavax and strengthens its vaccine portfolio	AQ
12-24	US stocks drift to more records on a holiday-shortened day of trading	AQ
12-24	Local Organ, Eye and Tissue Donors, Transplant Recipients and Living Donors to be Honored on the 2026 OneLegacy Donate Life Rose Parade(R) Float on New Year's Day	AQ
12-24	Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline	GL
12-24	Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis	GL
12-23	Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia	GL
12-23	Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma	GL
12-22	Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2025	PU
12-19	Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation	GL
12-18	Cytokinetics Announces NMPA Approval of MYQORZO in China for Patients with Obstructive Hypertrophic Cardiomyopathy	AQ
12-18	Claiming Your Drug Product Is Unique: Does That Mean It's Superior?	AQ
12-17	Availability of the Q4 2025 Aide memoire	GL
12-17	Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema	GL
12-15	Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis	GL
12-15	Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis	GL
12-11	Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases	GL
12-09	FDA opens safety review of injectable RSV drugs approved for babies and toddlers	AQ
12-04	Sanofi completes acquisition of Vicebio	GL
12-03	UPC Court Of Appeal Overturns Revocation Of Amgen's PCSK9 Antibody Patent And Clarifies The UPC's Inventive Step Approach (Amgen v Sanofi And Regeneron)	AQ
11-28	Sanofi invests 50 million euros in its Le Trait site to meet growing demand for anti-inflammatory drug Dupixent	AQ
11-25	Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria	GL
11-19	Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors	AQ